S&P 500   4,274.99 (+0.03%)
DOW   33,565.28 (-0.16%)
QQQ   354.00 (-0.06%)
AAPL   170.31 (-0.96%)
MSFT   311.99 (-0.05%)
META   293.06 (-1.97%)
GOOGL   129.66 (+0.85%)
AMZN   125.64 (-0.27%)
TSLA   238.57 (-2.27%)
NVDA   422.45 (+0.80%)
NIO   8.48 (+0.83%)
BABA   86.02 (+0.13%)
AMD   97.74 (+1.85%)
T   14.88 (-0.93%)
F   12.36 (-0.56%)
MU   67.75 (-0.28%)
CGC   0.92 (-0.75%)
GE   110.82 (+0.81%)
DIS   79.81 (-0.30%)
AMC   7.62 (-3.67%)
PFE   32.18 (-0.68%)
PYPL   57.38 (-2.63%)
NFLX   378.63 (-0.16%)
S&P 500   4,274.99 (+0.03%)
DOW   33,565.28 (-0.16%)
QQQ   354.00 (-0.06%)
AAPL   170.31 (-0.96%)
MSFT   311.99 (-0.05%)
META   293.06 (-1.97%)
GOOGL   129.66 (+0.85%)
AMZN   125.64 (-0.27%)
TSLA   238.57 (-2.27%)
NVDA   422.45 (+0.80%)
NIO   8.48 (+0.83%)
BABA   86.02 (+0.13%)
AMD   97.74 (+1.85%)
T   14.88 (-0.93%)
F   12.36 (-0.56%)
MU   67.75 (-0.28%)
CGC   0.92 (-0.75%)
GE   110.82 (+0.81%)
DIS   79.81 (-0.30%)
AMC   7.62 (-3.67%)
PFE   32.18 (-0.68%)
PYPL   57.38 (-2.63%)
NFLX   378.63 (-0.16%)
S&P 500   4,274.99 (+0.03%)
DOW   33,565.28 (-0.16%)
QQQ   354.00 (-0.06%)
AAPL   170.31 (-0.96%)
MSFT   311.99 (-0.05%)
META   293.06 (-1.97%)
GOOGL   129.66 (+0.85%)
AMZN   125.64 (-0.27%)
TSLA   238.57 (-2.27%)
NVDA   422.45 (+0.80%)
NIO   8.48 (+0.83%)
BABA   86.02 (+0.13%)
AMD   97.74 (+1.85%)
T   14.88 (-0.93%)
F   12.36 (-0.56%)
MU   67.75 (-0.28%)
CGC   0.92 (-0.75%)
GE   110.82 (+0.81%)
DIS   79.81 (-0.30%)
AMC   7.62 (-3.67%)
PFE   32.18 (-0.68%)
PYPL   57.38 (-2.63%)
NFLX   378.63 (-0.16%)
S&P 500   4,274.99 (+0.03%)
DOW   33,565.28 (-0.16%)
QQQ   354.00 (-0.06%)
AAPL   170.31 (-0.96%)
MSFT   311.99 (-0.05%)
META   293.06 (-1.97%)
GOOGL   129.66 (+0.85%)
AMZN   125.64 (-0.27%)
TSLA   238.57 (-2.27%)
NVDA   422.45 (+0.80%)
NIO   8.48 (+0.83%)
BABA   86.02 (+0.13%)
AMD   97.74 (+1.85%)
T   14.88 (-0.93%)
F   12.36 (-0.56%)
MU   67.75 (-0.28%)
CGC   0.92 (-0.75%)
GE   110.82 (+0.81%)
DIS   79.81 (-0.30%)
AMC   7.62 (-3.67%)
PFE   32.18 (-0.68%)
PYPL   57.38 (-2.63%)
NFLX   378.63 (-0.16%)
NYSE:QGEN

Qiagen (QGEN) Stock Forecast, Price & News

$39.51
-0.10 (-0.25%)
(As of 02:39 PM ET)
Compare
Today's Range
$39.24
$39.85
50-Day Range
$39.13
$47.22
52-Week Range
$38.98
$51.18
Volume
618,725 shs
Average Volume
964,255 shs
Market Capitalization
$9.01 billion
P/E Ratio
26.88
Dividend Yield
N/A
Price Target
$49.50

Qiagen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
35.0% Upside
$53.15 Price Target
Short Interest
Healthy
1.43% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.83
Upright™ Environmental Score
News Sentiment
0.60mentions of Qiagen in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
5.31%
From $2.07 to $2.18 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.70 out of 5 stars

Medical Sector

159th out of 963 stocks

Biological Products, Except Diagnostic Industry

22nd out of 159 stocks


QGEN stock logo

About Qiagen (NYSE:QGEN) Stock

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

QGEN Price History

QGEN Stock News Headlines

Qiagen's (QGEN) "Buy" Rating Reaffirmed at Citigroup
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
QIAGEN (QGEN) Extends QIAwave Product Line With New Kit
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Comparing Qiagen (NYSE:QGEN) & Finch Therapeutics Group (NASDAQ:FNCH)
QIAGEN's (QGEN) New API Streamlines Access to BKB Data
Berenberg Bank Reaffirms Their Buy Rating on Qiagen (QGEN)
Qiagen (QGEN) Receives a Buy from Citi
DZ BANK AG Sticks to Their Buy Rating for Qiagen (QGEN)
Qiagen (QGEN) was downgraded to a Hold Rating at Berenberg Bank
Kepler Capital Reaffirms Their Hold Rating on Qiagen (QGEN)
Jefferies Keeps Their Hold Rating on Qiagen (QGEN)
QIAGEN Reports Q2 Results
See More Headlines
Receive QGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Qiagen and its competitors with MarketBeat's FREE daily newsletter.

QGEN Company Calendar

Last Earnings
8/08/2023
Today
9/27/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Employees
6,178
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$49.50
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+25.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$423.21 million
Pretax Margin
20.86%

Debt

Sales & Book Value

Annual Sales
$2.14 billion
Cash Flow
$3.49 per share
Book Value
$15.22 per share

Miscellaneous

Free Float
207,480,000
Market Cap
$8.98 billion
Optionable
Optionable
Beta
0.37
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Thierry Bernard (Age 58)
    CEO, MD & Member of Management Board
    Comp: $2.67M
  • Dr. Roland Sackers (Age 54)
    CFO, MD & Member of Management Board
    Comp: $1.33M
  • Mr. Antonio Santos
    Sr. VP & Head of Global Operations
  • Mr. John Gilardi
    VP of Corp. Communications & Investor Relations
  • Ms. Stephany Foster (Age 44)
    Sr. VP & Head of HR
  • Dr. Thomas Schweins
    Sr. VP of Life Science Bus. Area
  • Dr. Thomas Theuringer
    Sr. Director & Head of External Communications
  • Mr. Jean-Pascal Viola
    Sr. VP & Head of Molecular Diagnostics Bus. Area
  • Dr. Jonathan G. Sheldon Ph.D. (Age 51)
    Sr. VP of Qiagen Digital Insights Bus. Area
  • Mr. Thomas Neidert
    VP of Global Treasury













QGEN Stock - Frequently Asked Questions

Should I buy or sell Qiagen stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" QGEN shares.
View QGEN analyst ratings
or view top-rated stocks.

What is Qiagen's stock price forecast for 2023?

6 Wall Street research analysts have issued 12 month target prices for Qiagen's shares. Their QGEN share price forecasts range from $40.00 to $60.00. On average, they anticipate the company's stock price to reach $49.50 in the next twelve months. This suggests a possible upside of 25.7% from the stock's current price.
View analysts price targets for QGEN
or view top-rated stocks among Wall Street analysts.

How have QGEN shares performed in 2023?

Qiagen's stock was trading at $49.87 at the beginning of 2023. Since then, QGEN shares have decreased by 21.1% and is now trading at $39.37.
View the best growth stocks for 2023 here
.

Are investors shorting Qiagen?

Qiagen saw a decrease in short interest in September. As of September 15th, there was short interest totaling 3,240,000 shares, a decrease of 16.1% from the August 31st total of 3,860,000 shares. Based on an average trading volume of 1,250,000 shares, the days-to-cover ratio is presently 2.6 days. Approximately 1.4% of the company's shares are sold short.
View Qiagen's Short Interest
.

When is Qiagen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our QGEN earnings forecast
.

How were Qiagen's earnings last quarter?

Qiagen (NYSE:QGEN) posted its earnings results on Tuesday, August, 8th. The company reported $0.51 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.50 by $0.01. The firm had revenue of $497 million for the quarter, compared to analysts' expectations of $492.21 million. Qiagen had a trailing twelve-month return on equity of 13.72% and a net margin of 17.04%. Qiagen's revenue for the quarter was down 8.6% on a year-over-year basis. During the same period last year, the company posted $0.51 earnings per share.

What guidance has Qiagen issued on next quarter's earnings?

Qiagen updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of $2.07- for the period, compared to the consensus estimate of $2.11. The company issued revenue guidance of $1.97B-, compared to the consensus revenue estimate of $2.05 billion.

What is Thierry Bernard's approval rating as Qiagen's CEO?

33 employees have rated Qiagen Chief Executive Officer Thierry Bernard on Glassdoor.com. Thierry Bernard has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Qiagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include NVIDIA (NVDA), QUALCOMM (QCOM), Gilead Sciences (GILD), Advanced Micro Devices (AMD), PayPal (PYPL), Netflix (NFLX), Pfizer (PFE), Cisco Systems (CSCO), Amgen (AMGN) and Lam Research (LRCX).

What is Qiagen's stock symbol?

Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."

Who are Qiagen's major shareholders?

Qiagen's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.31%), DekaBank Deutsche Girozentrale (1.45%), Perpetual Ltd (1.17%), Marshall Wace LLP (1.17%), State Street Corp (0.97%) and Barclays PLC (0.72%).

How do I buy shares of Qiagen?

Shares of QGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Qiagen's stock price today?

One share of QGEN stock can currently be purchased for approximately $39.37.

How much money does Qiagen make?

Qiagen (NYSE:QGEN) has a market capitalization of $8.98 billion and generates $2.14 billion in revenue each year. The company earns $423.21 million in net income (profit) each year or $1.47 on an earnings per share basis.

How many employees does Qiagen have?

The company employs 6,178 workers across the globe.

How can I contact Qiagen?

Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912. The official website for the company is www.qiagen.com. The company can be reached via phone at (177) 355-6600, via email at ir@qiagen.com, or via fax at 31-77-355-6658.

This page (NYSE:QGEN) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -